Φορτώνει......
Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features
Patients with chronic myeloid leukemia, treated with imatinib, who have a durable complete molecular response, might remain in complete molecular response after stopping treatment. Previous reports of patients stopping treatment in complete molecular response have included only patients with a good...
Αποθηκεύτηκε σε:
Κύριοι συγγραφείς: | , , , , , |
---|---|
Μορφή: | Artigo |
Γλώσσα: | Inglês |
Έκδοση: |
Ferrata Storti Foundation
2011
|
Θέματα: | |
Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3208693/ https://ncbi.nlm.nih.gov/pubmed/21828123 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.048165 |
Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|